Co-Diagnostics, Inc. reports developments in molecular diagnostics, including its patented platform for designing molecular diagnostic tests and its Co-Dx PCR platform. Company news commonly covers clinical and regulatory disclosures, commercialization activity through CoSara and CoMira joint ventures, intellectual property and technology updates, and operating and financial results.
Recurring updates also include material agreements, governance matters, capital-structure actions, and securities-listing developments. The company’s public disclosures connect its diagnostic-test pipeline, platform development, and commercialization strategy with financing, shareholder approvals, and other corporate actions.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced that its partner, Clinical Reference Laboratory (CRL), received FDA Emergency Use Authorization for the CRL Rapid Response™ COVID-19 saliva test. This self-administered test uses Co-Diagnostics' patented CoPrimer™ technology, enhancing sensitivity and specificity.
CEO Dwight Egan expressed confidence in the Co-Diagnostics platform, highlighting its potential to facilitate a safe return to normalcy. The Logix Smart COVID-19 test by Co-Diagnostics is also available for clinical laboratories in the US and other countries.